# Decipher Bioscineces

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/decipher-bioscineces

- Industry: Biotechnology
- Headquarters: Vancouver, Canada
- Website: www.decipherbio.com
- Latest round: Series B (Sep 30, 2013)
- Investors on record: 4

## About

Decipher Biosciences, Inc. specializes in providing genomic testing solutions for urologic cancers, enhancing personalized treatment options for patients through advanced insights derived from their proprietary tests.Decipher Biosciences, Inc. operates in the field of genomic testing for urologic cancers, focusing on personalized treatment approaches. Founded in 2008 and headquartered in Vancouver, Canada, the company was involved in a significant acquisition in February 2021 when Veracyte, Inc. acquired it for USD 250 million in cash and USD 350 million in stock. The acquisition indicates a strategic pivot to enhance Veracyte's portfolio in precision medicine. The company has recorded a total of 8 deals, with its most recent deal occurring on February 3, 2021. The founder's history and previous ventures are not publicly available.Decipher Biosciences, Inc. provides genomic tests designed specifically for urologic cancers, including its signature tests: Decipher® Prostate and Decipher® Bladder. The Decipher Prostate test offers actionable insights for treatment decisions in localized prostate cancer, while Decipher Bladder assists in informed treatment planning for bladder cancer. Their products primarily serve oncologists, urologists, and healthcare institutions across the United States, aimed at improving patient outcomes through individualized care strategies.Decipher Biosciences, Inc. derives revenue from its laboratory-developed tests (LDTs), specifically the Decipher Prostate and Decipher Bladder tests. The company engages directly with healthcare providers, who order these tests for their patients, and receives payment for each test conducted. The resulting comprehensive reports facilitate clinical decision-making. Additionally, their tests are covered by various insurance plans, enhancing accessibility for patients and contributing to the company’s revenue.Following its acquisition by Veracyte, Inc. in February 2021, Decipher Biosciences, Inc. is poised to leverage the financial backing from the deal to enhance its product offerings and expand its market reach. The company is expected to focus on launching new genomic tests targeting additional urologic cancers by 2023, thereby broadening its service portfolio. Furthermore, with the recent funding, Decipher aims to penetrate new geographic markets beyond the United States, specifically targeting Europe and Asia by 2025, to increase access to their precision medicine solutions.

## Funding rounds

- Series B, Sep 30, 2013 — Baird Capital Partners, Julip Run Capital, Merck Global Health Innovation Fund, Aeris Capital
- Series A, Jan 9, 2012 — Baird Capital Partners, Julip Run Capital, Aeris Capital

## Investors

- Baird Capital Partners (https://capitalatlas.ai/funds/baird-capital-partners) — Series A, Series B
- Julip Run Capital (https://capitalatlas.ai/funds/julip-run-capital) — Series A, Series B
- Aeris Capital — Series A, Series B
- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Series B